Abbvie (ABBV) PT Hiked to $160 at Truist Securities, Analyst Cites Underappreciated Pipeline of Rinvoq, Skyrizi & Other Approved Products
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $160.00 (from $135.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
